<?xml version="1.0" encoding="iso-8859-1" ?>
<rss version="2.0" xmlns:s="http://resources.bnet.com/">
<channel>
	<title><![CDATA[Allergan Inc. | Company News & Executive Profiles - AGN | BNET]]></title>
	<link><![CDATA[http://resources.bnet.com/topic/allergan+inc..html?i=11]]></link>
	<description><![CDATA[Latest company news & analysis, recent events, stock quotes, earning call transcripts, with profiles and descriptions of top business executives for Allergan Inc.]]></description>
	<s:counts start="0" returned="10" found="484" />
	<language>en-us</language>
	<item>
		<title><![CDATA[Why Allergan and Medicis Should Embrace the "Botox Tax" in Senate Health Bill]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/10005435/why-allergan-and-medicis-should-embrace-the-botox-tax-in-senate-health-bill/]]></link>
		<description><![CDATA[The idea that Botox is a civil rights issue is ludicrous -- and yet that is the line being pushed by Allergan AGN in its fight against the 5 percent "Botox tax" proposed in the Senate healthcare reform bill. Instead, Allergan and its rival, Medicis MRX, should embrace this new...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_bnet.gif" type="image/gif" />
		<pubDate>Fri, 20 Nov 2009 12:21:25 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/health+care.html"><![CDATA[Health Care]]></category>
		<category domain="http://resources.bnet.com/topic/allergan+inc..html"><![CDATA[Allergan Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/u.s.+senate.html"><![CDATA[U.S. Senate]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare+reform.html"><![CDATA[Healthcare Reform]]></category>
		<category domain="http://resources.bnet.com/topic/federal+government.html"><![CDATA[Federal Government]]></category>
		<category domain="http://resources.bnet.com/topic/taxes.html"><![CDATA[Taxes]]></category>
		<category domain="http://resources.bnet.com/topic/free+trade.html"><![CDATA[Free Trade]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/government.html"><![CDATA[Government]]></category>
		<category domain="http://resources.bnet.com/topic/financial+planning.html"><![CDATA[Financial Planning]]></category>
		<category domain="http://resources.bnet.com/topic/finance.html"><![CDATA[Finance]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">AGN</category>
		<category domain="tickers">AGN</category>
	</item>
	<item>
		<title><![CDATA[J&J Axes Evolence, Its "Too Lumpy" Dermal Filler; Allergan, Medicis Rejoice]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/10005205/j-allergan-medicis-rejoice/]]></link>
		<description><![CDATA[Johnson & Johnson JNJ has stopped marketing wrinkle filler Evolence, a little more than a year after it was launched. Doctors were informed of the news on Nov. 3. Kudos to Allergan AGN and Medicis MRX , marketers of Juvederm and Restylane, respectively: The rivals have successfully seen off the...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_bnet.gif" type="image/gif" />
		<pubDate>Mon, 09 Nov 2009 08:18:37 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/johnson+%2526+johnson.html"><![CDATA[Johnson & Johnson]]></category>
		<category domain="http://resources.bnet.com/topic/allergan+inc..html"><![CDATA[Allergan Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/marketing+research.html"><![CDATA[Marketing Research]]></category>
		<category domain="http://resources.bnet.com/topic/marketing.html"><![CDATA[Marketing]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">AGN</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">JNJ</category>
		<category domain="tickers">AGN,JNJ</category>
	</item>
	<item>
		<title><![CDATA[Allergan Q3 2009 Earnings Call Transcript]]></title>
		<link><![CDATA[http://www.bnet.com/2462-14055_23-358724.html]]></link>
		<description><![CDATA[ Question-and-Answer SessionOperator Thank you. Operator Instructions. Our first question comes from Frank Pinkerton, SunTrust. Frank Pinkerton - SunTrust Robinson Humphrey Hey. First of all, Dave I believe you made a comment around Dysport expanding the market versus cannibalizing it. Do you have any data point that Jim gave us...]]></description>
		<s:doctype><![CDATA[Earnings calls]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Thu, 29 Oct 2009 16:30:24 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/call+transcript.html"><![CDATA[Call Transcript]]></category>
		<category domain="http://resources.bnet.com/topic/allergan+inc..html"><![CDATA[Allergan Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/earnings.html"><![CDATA[Earnings]]></category>
		<category domain="http://resources.bnet.com/topic/glaucoma.html"><![CDATA[Glaucoma]]></category>
		<category domain="http://resources.bnet.com/topic/research+%2526+development.html"><![CDATA[Research & Development]]></category>
		<category domain="http://resources.bnet.com/topic/corporate+governance.html"><![CDATA[Corporate Governance]]></category>
		<category domain="http://resources.bnet.com/topic/business+operations.html"><![CDATA[Business Operations]]></category>
		<category domain="http://resources.bnet.com/topic/corporate+law.html"><![CDATA[Corporate Law]]></category>
		<category domain="http://resources.bnet.com/topic/seeking+alpha.html"><![CDATA[Seeking Alpha]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">AGN</category>
		<category domain="tickers">AGN</category>
	</item>
	<item>
		<title><![CDATA[Earnings Preview: Allergan]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F169570-earnings-preview-allergan%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Allergan AGN is expected to report Q3 earnings on  Thursday, October 29 before the market open with a conference call scheduled for  11am ET.  Guidance Analysts are looking for EPS of 70c on revenue of $1.08B. The consensus  range is 67c-72c for EPS, and $1.05B-$1.11B for...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Wed, 28 Oct 2009 11:50:16 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/theflyonthewall.com.html"><![CDATA[theflyonthewall.com]]></category>
		<category domain="http://resources.bnet.com/topic/allergan+inc..html"><![CDATA[Allergan Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">AGN</category>
		<category domain="tickers">AGN</category>
	</item>
	<item>
		<title><![CDATA[Allergan's "Botox Parties" Could Spread HIV as Single-Use Vials Are Re-Used, Suit Claims]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/10004611/allergans-botox-parties-could-spread-hiv-as-single-use-vials-are-re-used-suit-claims/]]></link>
		<description><![CDATA[Allergan pushes "Botox parties" that put people at risk of HIV and Hepatitis because a "single-use" vial of the drug is used multiple times on different guests, according to a federal lawsuit filed in California. Doctors can only make a profit using Botox if they re-use the "single-use" vials that...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_bnet.gif" type="image/gif" />
		<pubDate>Mon, 05 Oct 2009 08:03:53 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/allergan+inc..html"><![CDATA[Allergan Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/hiv+virus.html"><![CDATA[HIV Virus]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">AGN</category>
		<category domain="tickers">AGN</category>
	</item>
	<item>
		<title><![CDATA[Allergan Insists DOJ Subpoena and Lawsuit v. FDA on Botox Are Unlinked]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/10004593/allergan-insists-doj-subpoena-and-lawsuit-v-fda-on-botox-are-unlinked/]]></link>
		<description><![CDATA[Allergan told investors that the suit it filed against the FDA to allow it more freedom to discuss off-label uses of Botox has nothing to do with a Department of Justice probe that has cost the company $7.4 million. by Jim Edwards]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_bnet.gif" type="image/gif" />
		<pubDate>Fri, 02 Oct 2009 13:51:04 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/lawsuit.html"><![CDATA[Lawsuit]]></category>
		<category domain="http://resources.bnet.com/topic/fda.html"><![CDATA[FDA]]></category>
		<category domain="http://resources.bnet.com/topic/allergan+inc..html"><![CDATA[Allergan Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/u.s.+department+of+justice.html"><![CDATA[U.S. Department Of Justice]]></category>
		<category domain="http://resources.bnet.com/topic/federal+government.html"><![CDATA[Federal Government]]></category>
		<category domain="http://resources.bnet.com/topic/government.html"><![CDATA[Government]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">AGN</category>
		<category domain="tickers">AGN</category>
	</item>
	<item>
		<title><![CDATA[Allergan Gets Warning Letter on Latisse for Omitting Infection Risk]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/10004342/allergan-gets-warning-letter-on-latisse-over-too-small-risk-info/]]></link>
		<description><![CDATA[Allergan has already caught its first warning letter from the FDA for downplaying the risks of Latisse, its new eyelash lengthener, less than a year into its launch. by Jim Edwards]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_bnet.gif" type="image/gif" />
		<pubDate>Thu, 17 Sep 2009 07:45:58 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/infection.html"><![CDATA[Infection]]></category>
		<category domain="http://resources.bnet.com/topic/allergan+inc..html"><![CDATA[Allergan Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/federal+government.html"><![CDATA[Federal Government]]></category>
		<category domain="http://resources.bnet.com/topic/security.html"><![CDATA[Security]]></category>
		<category domain="http://resources.bnet.com/topic/government.html"><![CDATA[Government]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">AGN</category>
		<category domain="tickers">AGN</category>
	</item>
	<item>
		<title><![CDATA[FDA Gives Allergan a Stats Lesson in Bold Type]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/10003850/fda-gives-allergan-a-stats-lesson-in-bold-type/]]></link>
		<description><![CDATA[Could the FDA be signalling a more aggressive regulatory stance under the Obama administration  through its use of dramatic adverbs and bold type? That's one way to read a warning letter the FDA sent to Allergan regarding a journal ad for its Aczone acne product. by Jim Edwards]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_bnet.gif" type="image/gif" />
		<pubDate>Mon, 24 Aug 2009 07:59:13 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/fda.html"><![CDATA[FDA]]></category>
		<category domain="http://resources.bnet.com/topic/allergan+inc..html"><![CDATA[Allergan Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/federal+government.html"><![CDATA[Federal Government]]></category>
		<category domain="http://resources.bnet.com/topic/government.html"><![CDATA[Government]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">AGN</category>
		<category domain="tickers">AGN</category>
	</item>
	<item>
		<title><![CDATA[In Allergan's Search for Baldness Cure, Does the Stumptailed Macaque Hold the Key?]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/10003613/in-allergans-search-for-baldness-cure-does-the-stumptailed-macaque-hold-the-key/]]></link>
		<description><![CDATA[There are few good indications to whether Allergan's Latisse could also cure male-pattern baldness. The stumptailed macaque pictured, a monkey that goes bald, may hold clue. BNET reported yesterday that Allergan is planning trials of Latisse (the eyelash-enhancing drug that was developed from glaucoma drug Lumigan) to see if it...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_bnet.gif" type="image/gif" />
		<pubDate>Wed, 12 Aug 2009 09:33:27 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/allergan+inc..html"><![CDATA[Allergan Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">AGN</category>
		<category domain="tickers">AGN</category>
	</item>
	<item>
		<title><![CDATA[Is Allergan's Latisse Also a Cure for Baldness?]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/10003588/is-allergans-latisse-also-a-cure-for-baldness/]]></link>
		<description><![CDATA[Allergan believes it may have a cure for baldness in the form of Latisse/Lumigan, its glaucoma drug-cum-eyelash enhancer. EVP R&D Scott Whitcup told investors by Jim Edwards]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_bnet.gif" type="image/gif" />
		<pubDate>Tue, 11 Aug 2009 12:18:53 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/cure.html"><![CDATA[Cure]]></category>
		<category domain="http://resources.bnet.com/topic/allergan+inc..html"><![CDATA[Allergan Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/financial+accounting.html"><![CDATA[Financial Accounting]]></category>
		<category domain="http://resources.bnet.com/topic/finance.html"><![CDATA[Finance]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">AGN</category>
		<category domain="tickers">AGN</category>
	</item>
</channel>
</rss>
